8-K: Vaxart Reports Strong 2025 Results, Advances Vaccine Pipeline

Vaxart announced a significant financial turnaround in 2025 with net income and extended cash runway, alongside key advancements in its COVID-19 and norovirus vaccine programs.

Summary

• Vaxart reported a net income of $16.3 million for the full year 2025, a significant improvement from a net loss of $66.9 million in 2024.
• Revenue for the full year 2025 surged to $237.3 million, up from $28.7 million in 2024, primarily driven by government contracts and the Dynavax collaboration.
• Cash, cash equivalents, and investments totaled $63.8 million as of December 31, 2025, providing a cash runway into the second quarter of 2027.
• The COVID-19 program advanced with a worldwide collaboration with Dynavax and completed enrollment of approximately 5,400 participants in its Phase 2b trial.
• Topline data from the 400-person sentinel cohort of the Phase 2b COVID-19 trial are anticipated early in the second quarter of 2026, with full trial data expected in the fourth quarter of 2026.
• Positive Phase 1 results for the oral norovirus vaccine were published in January 2026, demonstrating safety, immunogenicity in lactating women, and passive antibody transfer to infants via breast milk.
• Vaxart plans to initiate its next norovirus clinical trial in 2026, contingent on securing a partnership or other funding.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to the significant financial turnaround, substantial revenue growth, extended cash runway, and strategic partnership for its lead COVID-19 program. Positive clinical data for the norovirus vaccine further enhances the company's pipeline value, despite increased R&D expenses and the need for future funding for the norovirus program.

Positives

• Achieved a net income of $16.3 million for the full year 2025, a substantial improvement from a $66.9 million net loss in 2024.
• Reported a significant increase in revenue to $237.3 million in 2025, compared to $28.7 million in 2024, driven by government contracts and the Dynavax collaboration.
• Extended cash runway into the second quarter of 2027, with $63.8 million in cash, cash equivalents, and investments as of December 31, 2025.
• Secured a worldwide collaboration with Dynavax for the COVID-19 program, providing a well-funded path forward and industry validation.
• Completed enrollment of approximately 5,400 participants for the COVID-19 Phase 2b trial, progressing as planned.
• Published positive Phase 1 clinical results for the norovirus vaccine, demonstrating passive antibody transfer to breastfed infants, potentially increasing its public health value.

Negatives

• Research and development expenses significantly increased to $201.6 million in 2025 from $74.2 million in 2024, primarily due to the COVID-19 vaccine candidate's clinical trial expenses.
• Initiation of the next norovirus clinical trial in 2026 is pending a partnership or other funding, indicating a reliance on external capital for this program's advancement.

Risks

• Uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates.
• Possibility of unfavorable new clinical data and further analyses of existing clinical data.
• Clinical trial data are subject to differing interpretations and assessments by regulatory authorities.
• Regulatory authorities may not be satisfied with the design of and results from the clinical studies.
• Decisions by regulatory authorities impacting labeling, manufacturing processes, and safety could affect the availability or commercial potential of any product candidate, including the possibility that product candidates may not be approved by the FDA or non-U.S. regulatory authorities.
• Even if approved by regulatory authorities, product candidates may not achieve broad market acceptance.
• A Vaxart collaborator may not attain development and commercial milestones.
• Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's or its partners' control.
• Difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations.
• Inability to obtain, maintain, and enforce necessary patent and other intellectual property protection.
• Capital resources may be inadequate.
• Ability to resolve pending legal matters.
• Ability to obtain sufficient capital to fund operations on terms acceptable to Vaxart, if at all.
• Impact of government healthcare proposals and policies.
• Competitive factors.

Future Outlook

Vaxart anticipates releasing safety data from the sentinel cohort of its Phase 2b COVID-19 trial early in the second quarter of 2026, followed by full topline data from all participants in the fourth quarter of 2026. The company plans to initiate its next norovirus clinical trial in 2026, contingent on securing a partnership or other funding. Vaxart also expects its current cash runway to extend into the second quarter of 2027.

Management Comments

• Steven Lo, CEO, stated that the COVID-19 program reached a major strategic inflection point in the fourth quarter with the worldwide collaboration with Dynavax, which provides a well-funded path forward and reinforces industry recognition of their mucosal vaccine platform.
• Lo highlighted the rapid progress toward two critical milestones: the release of 12-month data from the 400-person sentinel cohort expected early in Q2 2026, and the full readout of comparative efficacy and safety from the main cohort of approximately 5,000 participants in the Phase 2b trial, expected in Q4 2026.
• Lo emphasized that these datasets will be pivotal in demonstrating whether their oral pill can provide the full year effectiveness believed to stem from the systemic and mucosal immune response required to manage endemic COVID-19.
• Lo noted that norovirus remains a significant unmet need globally with no approved vaccine, and the recently published data demonstrating passive antibody transfer to breastfed infants potentially increases the public health value of their norovirus vaccine candidate.
• Lo believes the new norovirus data will enhance Vaxart's ability to secure a partnership or other funding to advance the norovirus program.

Industry Context

StockSavvy.ai notes that Vaxart's focus on oral recombinant pill vaccines positions it uniquely within the biotechnology sector, aiming to address significant unmet medical needs like norovirus, where no approved vaccine currently exists. The collaboration with Dynavax for its COVID-19 program signals external validation of its proprietary mucosal vaccine platform, a key differentiator in a competitive vaccine landscape dominated by injectable technologies. The potential for passive antibody transfer in infants via breast milk for norovirus could open new market opportunities and public health applications, distinguishing Vaxart's approach from traditional vaccine development.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for increased value due to strong financial performance, strategic partnerships, and clinical pipeline advancements, but also exposure to R&D risks and future funding needs.
• Employees: Continued employment and active engagement in clinical development and research.
• Customers (future): Potential for new oral vaccine options for COVID-19 and norovirus.
• Partners (Dynavax): Ongoing collaboration and shared progress in the COVID-19 vaccine program.
• Regulatory Authorities: Will assess clinical trial data and regulatory submissions for potential approvals.

Next Steps

• Host a conference call on March 12, 2026, to discuss the business update and financial results.
• Host a live stockholder fireside chat on March 13, 2026.
• Anticipate safety data from the 400-person sentinel cohort of the COVID-19 Phase 2b trial early in the second quarter of 2026.
• Anticipate topline data from all participants in the COVID-19 Phase 2b trial in the fourth quarter of 2026.
• Plan to initiate the next norovirus clinical trial in 2026, pending a partnership or other funding.

Key Dates

Recommendation

The company demonstrated a remarkable financial turnaround, moving from a significant loss to profitability, coupled with substantial revenue growth. The strategic partnership with Dynavax validates its core technology and provides a funded path for its lead COVID-19 program, which is nearing critical data readouts. Positive early data for the norovirus vaccine also adds significant pipeline value. While R&D expenses are high and future funding for the norovirus program is contingent, the overall progress and financial health indicate strong momentum and potential for future growth, making it an attractive investment.

Keywords

Vaxart, VXRT, oral vaccine, COVID-19 vaccine, norovirus vaccine, biotechnology, clinical trial, Phase 2b, Dynavax, BARDA, financial results, vaccine development, mucosal immunity